<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814097</url>
  </required_header>
  <id_info>
    <org_study_id>SPIHF-203</org_study_id>
    <secondary_id>2015-005615-32</secondary_id>
    <nct_id>NCT02814097</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction</brief_title>
  <official_title>A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SCIRENT Clinical Research and Science d.o.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with
      stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4
      weeks treatment with subcutaneous MTP-131 (elampretide) on left ventricular function.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2, 2016</start_date>
  <completion_date type="Actual">June 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the delta in E/e' at rest exercise measured with echocardiography between the elamipretide and placebo groups</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the change at rest and during submaximal stress in LV systolic global longitudinal strain (GLS) between the elamipretide and placebo groups at the end of the 4-week treatment period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change in 6-minute walking distance, between the elamipretide and placebo groups at the end of the 4-week treatment period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the change in NT-proBNP, between the elamipretide and placebo groups at the end of the 4-week treatment period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the percent of patients on elamipretide versus placebo presenting with TEAEs and SAEs, including changes in biomarkers of myocardial damage and changes in markers of renal function</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>40 mg elamipretide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg elamipretide once daily for 28 consecutive days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 28 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elamipretide</intervention_name>
    <description>Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days</description>
    <arm_group_label>40 mg elamipretide</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Bendavia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous injection of placebo administered once daily for 28 consecutive days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥45 and &lt;80 years.

          -  Symptomatic heart failure (i.e. NYHA II or III) due to HFpEF for at least 6 months
             prior to study start

          -  Evidence of HFpEF: LVEF ≥45% and E/e´&gt;10 and NT-pro-BNP &gt;220 pg/ml (sinus rhythm) / &gt;
             600 pg/mL (atrial fibrillation)

          -  An exercise-induced increase in E/e' of at least 1.5 units during stress
             echocardiography assessment.

          -  Heart failure is considered to be stable, in the judgment of the investigator, and no
             hospitalization for HFpEF or changes in dose regimen of pharmacologic treatment for HF
             has occurred within 1 month prior to the Screening Visit.

          -  Treatment with appropriate pharmacologic therapy to manage underlying risk factors
             according to current guidelines.

          -  Women of childbearing potential must agree to use 1 of the following methods of birth
             control from the date they sign the ICF until two months after the last dose of study
             medication:

             a) Abstinence, b) surgically sterilized male partner, or c) barrier method And
             hormonal contraception

          -  Women of child-bearing potential must have a negative serum pregnancy test at baseline

          -  Willing and able to provide signed informed consent form (ICF) prior to participation
             in any study-related procedures

        Exclusion Criteria:

          -  Probable alternative diagnoses that in the opinion of the investigator could account
             for the patient's symptoms e.g. severe pulmonary dysfunction or severe asthma

          -  LVEF &lt;45% (at the moment of enrollment or in medical history)

          -  Coronary or peripheral revascularization procedures, valvular procedures, OR any major
             surgical procedure within 3 months prior to the Screening Visit.

          -  Acute coronary syndrome (ACS), stroke or transient ischemic attack (TIA) within 3
             months prior to the Screening Visit.

          -  Uncontrolled hypertension defined as a systolic blood pressure (BP) &gt;160 mm Hg or a
             diastolic BP &gt;100 mm Hg on at least 2 consecutive readings that will require a change
             in anti-hypertensive treatment during the study period.

          -  Active cancer or undergoing chemotherapy within previous 6 months

          -  Total bilirubin &gt;2x the upper limit of normal (ULN) in the absence of Gilbert's
             Syndrome (M. Meulengracht) and liver enzymes (alanine aminotransferase [ALT] and/or
             aspartate aminotransferase [AST] and/or alkaline phosphatase) elevation &gt;3xULN

          -  Estimated glomerular filtration rate &lt;30 mL/min, by MDRD

          -  Known active drug or alcohol abuse within 1 year of the Screening Visit.

          -  Use of other investigational drugs at the time of enrolment, or within 30 days or 5
             half-lives of enrolment

          -  Treatment with spironolactone or eplerenone for less than 3 months at study start

          -  Treatment with dabigatran

          -  Treatment with valsartan/sacubitril

          -  Female subjects who are pregnant, planning to become pregnant, or lactating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Center</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Clinic for Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Dr Dragiša Mišović-Dedinje&quot;, Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Zvezdara&quot;, Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Bežanijska Kosa&quot;, Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center &quot;Zemun&quot;, Department of Cardiology</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Niš, Clinic for Cardiology</name>
      <address>
        <city>Niš</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Cardiovascular Diseases Vojvodina, Clinic for Cardiology</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2016</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>HFpEF</keyword>
  <keyword>elamipretide</keyword>
  <keyword>MTP-131</keyword>
  <keyword>Bendavia™</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

